Celldex Therapeutics, Inc. (CLDX) shares are up 0.70% to $24.90 in pre-market trading Tuesday following the company’s fourth quarter earnings results.
The clinical-stage firm reported earnings of ($0.36) per share on revenues of $1.5 million, up 150% from a year ago. Analysts were expecting EPS of ($0.34) on revenues of $490K.
Net loss came in at $31.8 million, or ($0.36) per share, for the fourth quarter of 2014 and $118.1 million, or ($1.32) per share, for the twelve months ended Dec. 31, 2014, compared to a net loss of $22.1 million, or ($0.27) p/sh and $81.6 million, or ($1.02) p/sh for the comparable periods in 2013.
On valuation measures, Celldex Therapeutics Inc. shares, which currently have an average 3-month trading volume of 2.07 million shares, have a median Wall Street price target on the name of $33.00 with a high target of $45.00. Currently ticker boasts 9 ‘Buy’ endorsements, compared to no ’Holds’ and no ‘Sell’.
Profitability-wise, CLDX has a t-12 operating margin and price/sales of (4,122%) and 811.85, respectively. The $2.22 billion market cap company reported $201 million in cash vs. zero in debt in its most recent quarter.
CLDX currently prints a one year loss of about 22%, and a year-to-date return of around 35.50%.
The chart below shows where the equity has traded over the last 52 weeks.
Celldex Therapeutics Inc. is a Hampton, New Jersey- based biopharmaceutical company that focuses on the development of novel therapeutics for human health care primarily in the United States.